RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancer

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report.”

J&J tackles medical illustration inequity with free database of diverse images

Johnson & Johnson wants to change the status quo in medical illustrations with more Black, brown and indigenous depictions. Its “Illustrate Change” campaign is centered

July 4, 2023

Neighborhoods with higher opportunity or lower vulnerability linked to lower risk of pediatric asthma

Residence in neighborhoods with higher opportunity or lower vulnerability in early life may be associated with a decreased risk of pediatric asthma, according to a

August 28, 2023

American Psychedelic Practitioners Association Retains The Daschle Group as Government Affairs Counsel | Psychedelic Invest

APPA and The Daschle Group will work together to educate members of Congress and federal agencies about psychedelic-assisted therapy. The American Psychedelic Practitioners Association (APPA), the

September 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.